DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Aaboe K, Knop F, Vilsbøll T. et al
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents
degradation of peptide YY and improves glucose and non-glucose induced insulin
secretion in patients with type 2 diabetes mellitus.
Diabetes, Obesity and Metabolism 2010;
12: 323-333
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.